Lenz Therapeutics, Inc. · NASDAQ:LENZ
Lenz Therapeutics — Investor Presentation (October 2026)
20 slides from Lenz Therapeutics's investor presentation, October 2026
Slide 1: LENZ Therapeutics Corporate Presentation
LENZ Therapeutics Corporate Presentation 1
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are
Slide 3: Unblurring near vision for 128M US presbyopes
Unblurring near vision for 128M US presbyopes Only FDA-approved eye drop with potential for providing seamless vision for the full workday for the vast majority of 128M US presbyopes VIZZ launched in October 2025 and widely available 50% Quarter over Quarter Q3 growth; 110K total TRx since launch #1
Slide 4: Problem
Problem Presbyopia is the inevitable loss of near vision people in the US1 $ potential market opportunity Adults 50+ lose on average 1.5 lines of near vision per 6 years2 4
Slide 5: Majority of presbyopes are interested in an eye drop solution
Majority of presbyopes are interested in an eye drop solution Over 60% of 128M presbyopes in the US would consider an eye drop solution with clear early adopter segments3 Contact lens wearers Post-LASIK patients Active lifestyle consumers Contact lens wearers enjoy Post-refractive surgery patients A
Slide 6: VIZZ launched in Oct 2025
VIZZ launched in Oct 2025 The first and only pupil-selective miotic with potential to meet needs of all presbyopes and provide best-in-class potential for near vision improvement 6
Slide 7: Aceclidine is the only pupil-selective miotic
Aceclidine is the only pupil-selective miotic Active ingredient in VIZZ® Active ingredient in QLOSITM and VUITY® Active ingredient in YuvezziTM Reference: Ishikawa H, DeSantis L, Patil PN. Selectivity of muscarinic agonists including (+/-)-aceclidine and antimuscarinics on the human intraocular musc
Slide 8: VIZZ is the only aceclidine-based eye drop that selectively targets the pupil
VIZZ is the only aceclidine-based eye drop that selectively targets the pupil Aceclidine, the active ingredient in VIZZ: Is a pupil-selective miotic of patients achieved the ideal pupil size (<2mm) to restore Avoids overstimulating the ciliary muscle near vision4 8
Slide 9: VIZZ lasts up to hours with a once-daily dose
VIZZ lasts up to 10 hours with a From 1st dose: once-daily dose % of participants achieving ≥2- and ≥3-line near vision improvement Works fast of patients improved their near vision by 2 lines or more within 30 minutes Participants (%) Best-in-class of patients improved their near vision by 3 lines
Slide 10: VIZZ achieved 20/40 functional near vision for up to hours
VIZZ achieved 20/40 functional near vision for up to 10 hours patients achieved 20/40 at 10 hours Participants (%) Hours Day 1, CLARITY 1 & 2, analysis of binocular distance-corrected near vision with logMAR ≤0.3 (~20/40 or J3). 10
Slide 11: VIZZ was well tolerated
VIZZ was well tolerated No serious treatment- related adverse events <4% discontinuation due to treatment-related adverse events The majority of adverse reactions were mild, transient, and self-resolving. There were no reported retinal tears or detachments with VIZZ in clinical trials. 11
Slide 12: A clear strategy for commercialization
A clear strategy for commercialization 1 Doctors to recommend us Educate 15,000 ECPs about our VIZZ and its unique MOA 2 Consumers by name to request us DTC advertising that motivates consumers to visit an ECP 3 Seamless journey to use Consumer journey that facilitates instant access to VIZZ 12
Slide 13: Doctors to recommend us
Doctors to recommend us Awareness of VIZZ Confidence in VIZZ Willingness to Rx > 90% ECP aided and > 80% Establishing efficacy confidence Over 15,000 Prescribing ECPs unaided awareness as of July through ECP testimonials, all OD and over 75% prescribing more 2026 medical team, podium presence, than
Slide 14: Consumers to request us by name
Consumers to request us by name 1 Strong 2026 DTC media plan with Sarah Jessica Parker as Breaking through the clutter campaign spokesperson, national PR outreach fueling VIZZ’s proven word-of-mouth uptake 2 Belief in the product Engaging consumer website, clear simple messaging supported by social
Slide 15: Seamless journey to use
Seamless journey to use Through Retail, ePharmacy and Telehealth (launched July 2026) $ 79 1-month supply (25 vials) $ 198 ( $ 66/month) Save more with a 3-month supply (75 vials) Cash pay with no prior authorization required. HSA/FSA eligible. 15
Slide 16: Blockbuster potential in largest eye care market
Blockbuster potential in largest eye care market Huge patient population Real patient feedback Blockbuster potential would seriously consider a at conservative 6% adoption or once-daily drop for presbyopia1 ~8M users and 42% refill rate would continue to use 1-month supply (25 vials) VIZZ after the
Slide 17: VIZZ broad exclusivity and patent protection layers
VIZZ broad exclusivity and patent protection layers Ongoing brand equity of -- 8 Granted US patents up to 2044 -- US NCE regulatory exclusivity through 2030 17
Slide 18: Global expansion under way
Global expansion under way 11 ex-US dossiers under review; first approval anticipated as early as Q4 2026* 11 Ex-US dossiers submitted and +3 Additional regulatory under review globally submissions for approval expected by YE’26 Up to 5 Potential ex-US regulatory 5 Current ex-US partners, plus appro
Slide 19: Appendix
Appendix em (ececlidine ophthalmic solution) 144%
Slide 20: References
References 1. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia, Fricke, Timothy, et al, American Academy of Ophthalmology, vol 125, number 10, Oct 2018. 2. Progression of Near Vision Loss and Incidence of Near Vision Impairment in an Adult Chinese Population, Han, Xi
LENZ Therapeutics — Investor Presentation (October 2026) on 6ix